Mercy BioAnalytics is a biotechnology company developing blood-based tests for the early detection of cancer using its proprietary Mercy Halo™ liquid biopsy platform. By analyzing tumor-derived extracellular vesicles in the bloodstream, the company aims to identify cancers—initially ovarian and lung—at their earliest, most treatable stages to improve survival and expand access to effective screening.